Abstract
Kidney cancer research in 2014 was characterized by a diverse array of studies. Advances were made in both the localized and the metastatic renal cell carcinoma (RCC) arenas. Importantly, significant progress was also made in our understanding of the underpinnings of RCC tumorigenesis and progression.
| Original language | English |
|---|---|
| Pages (from-to) | 69-70 |
| Number of pages | 2 |
| Journal | Nature Reviews Gastroenterology and Hepatology |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis Inhibitors/therapeutic use
- Carcinogenesis
- Carcinoma, Renal Cell/genetics
- Disease Progression
- Humans
- Indazoles
- Indoles/therapeutic use
- Kidney Neoplasms/genetics
- Neoplasm Metastasis
- Nephrectomy/methods
- Nephrons
- Organ Sparing Treatments
- Pyrimidines/therapeutic use
- Pyrroles/therapeutic use
- Sulfonamides/therapeutic use
- Sunitinib
Fingerprint
Dive into the research topics of 'Kidney cancer in 2014: Key advances promise progress for kidney cancer patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver